

Pharmacy Policy

Step Therapy – Glaucoma

Policy Number: 9.913

Version Number: 2.0

Version Effective Date: 3/1/2022

Product Applicability **All Plan⁺ Products**

Well Sense Health Plan

New Hampshire Medicaid

Boston Medical Center HealthNet Plan

MassHealth - MCO

MassHealth - ACO

Qualified Health Plans/ConnectorCare/Employer Choice

Direct

Senior Care Options

Note: Disclaimer and audit information is located at the end of this document.

Prior Authorization Policy

POLICY STATEMENT:

A step therapy program has been developed to encourage the use of Step-1 products prior to the use of a Step-2 product, without interrupting existing therapy. If the step therapy rule is not met for a Step-2 agent at the point of service, coverage will be determined by the step therapy criteria below. All approvals are provided for 1 year in duration.

Standard Criteria:

The plan may authorize coverage of the products in the appendix for all FDA indications not otherwise excluded and for members meeting the following criteria when step therapy is not met at point of sale from claims history:

* Plan refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. The Plan operates in Massachusetts under the trade name Boston Medical Center HealthNet Plan and in other states under the trade name Well Sense Health Plan.

1. Prescribers must provide documentation (including trial outcome) that the member has tried and failed the appropriate number of Step 1 agents as indicated in Appendix A and in the coverage criteria requirements. **OR**
2. Prescriber must provide documentation that the member has a contraindication to or other clinical rationale preventing the use of ALL Step 1 agents indicated in Appendix A.

Appendix A: Step Therapy Details

Step 1	Glaucoma Agents	
	Step 2	Coverage Criteria
Latanoprost Opth Soln 0.005%	Bimatoprost Solution 0.03 % Ophthalmic Lumigan (bimatoprost) 0.01% Ophthalmic Zioptan (Tafluprost/PF) Solution 0.0015 % Ophthalmic Travoprost Solution 0.004 % Ophthalmic	A Step 2 Agent will be covered when pharmacy claims indicate a trial of a Step 1 Agent in the last 130 days

1. American Academy of Ophthalmology Corneal/External Disease Panel. Preferred Practice Pattern Guidelines. Glaucoma Summary Benchmarks. San Francisco, CA: American Academy of Ophthalmology; 2020. Available at: <http://www.aao.org/ppp>. Accessed Sept. 2021.
2. Azopt Suspension 1 % Ophthalmic Solution [package insert]. Alcon Laboratories. Fort Worth Texas. Accessed Sept. 2021.
3. Brimatoprost Solution 0.03% [package insert]. Allergan. Irvine, CA. Accessed 2021.
4. Lumigan (bimatoprost ophthalmic solution) [prescribing information]. Madison NJ: Allergan USA, Inc; Accessed Sept. 2021..
5. Travoprost Opth Soln 0.004% [package insert]. Alcon Laboratories. Fort Worth Texas. Accessed Sept. 2021.
6. Xalatan (Lantanoprost) [package insert]. Pfizer, Puurs Belgium. Accessed Sept 2021.

Original Approval Date	Original Effective Date	Policy Owner	Approved by
9/10/2020	1/1/2021	Pharmacy Services	Pharmacy & Therapeutics (P&T) Committee

Policy Revisions History

* Plan refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. The Plan operates in Massachusetts under the trade name Boston Medical Center HealthNet Plan and in other states under the trade name Well Sense Health Plan.

Policy Revisions History

Review Date	Summary of Revisions	Revision Effective Date	Approved by
9/10/2020	9.087 Step Therapy Policy retired, new policy created. Updated policy to align with 2021 formulary. Changed approval duration from 2 to 1 year. Changed trial duration from 120 to 130 days	1/1/2021	P&T Committee
11/11/2021	No recommended changes.	3/1/2022	P&T Committee

Next Review Date

11/2022

Other Applicable Policies

Reference to Applicable Laws and Regulations, If Any

Disclaimer Information

Medical Policies are the Plan's guidelines for determining the medical necessity of certain services or supplies for purposes of determining coverage. These Policies may also describe when a service or supply is considered experimental or investigational, or cosmetic. In making coverage decisions, the Plan uses these guidelines and other Plan Policies, as well as the Member's benefit document, and when appropriate, coordinates with the Member's health care Providers to consider the individual Member's health care needs.

Plan Policies are developed in accordance with applicable state and federal laws and regulations, and accrediting organization standards (including NCQA). Medical Policies are also developed, as appropriate, with consideration of the medical necessity definitions in various Plan products, review of current literature, consultation with practicing Providers in the Plan's service area who are medical experts in the particular field, and adherence to FDA and other government agency policies. Applicable state or federal mandates, as well as the Member's benefit document, take precedence over these guidelines. Policies are reviewed and updated on an annual basis, or more frequently as needed. Treating providers are solely responsible for the medical advice and treatment of Members.

The use of this Policy is neither a guarantee of payment nor a final prediction of how a specific claim(s) will be adjudicated. Reimbursement is based on many factors, including member eligibility and benefits on the date of service; medical necessity; utilization management guidelines (when applicable); coordination of benefits; adherence with applicable Plan policies and procedures; clinical coding criteria; claim editing logic; and the applicable Plan – Provider agreement.

* Plan refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. The Plan operates in Massachusetts under the trade name Boston Medical Center HealthNet Plan and in other states under the trade name Well Sense Health Plan.